Genetic basis of susceptibility to teratogen induced birth defects

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 157, Issue 3, 2011, Pages 215-226

  Wlodarczyk, Bogdan J ^a   Palacios, Ana M ^b   Chapa, Claudia J ^b   Zhu, Huiping ^c   George, Timothy M ^a   Finnell, Richard H ^d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Clinical genetics and neural tube defects ^*  (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d The University of Texas at Austin   (United States)

Author keywords

Birth defects; Gene environment interaction; Genome; Mutations; Teratogen

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; CIGARETTE SMOKE; FOLIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BIRTH DEFECT; CIGARETTE SMOKING; EMBRYO DEVELOPMENT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GLUCOSE METABOLISM; HEREDITY; HUMAN; HYPERGLYCEMIA; NEURAL TUBE DEFECT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TERATOGENESIS; TERATOLOGY;

ABNORMALITIES, DRUG-INDUCED; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PREGNANCY; TERATOGENS;

ANIMALIA;

EID: 79960555620     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30314     Document Type: Article

References (185)

1. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW. 2004. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75: 1575-1583.
2. Akazawa M, Akazawa S, Hashimoto M, Akashi M, Yamazaki H, Tahara D, Yamamoto H, Yamaguchi Y, Nakanishi T, Nagataki S. 1989. Effects of brief exposure to insulin-induced hypoglycemic serum during organogenesis in rat embryo culture. Diabetes 38: 1573-1578.
3. Anderson JL, Waller DK, Canfield MA, Shaw GM, Watkins ML, Werler MM. 2005. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiology 16: 87-92.
4. Au KS, Ashley-Koch A, Northrup H. 2010. Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev Disabil Res Rev 16: 6-15.
5. Azarbayjani F, Danielsson BR. 1998. Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: A common teratogenic mechanism for antiepileptic drugs? Teratology 57: 117-126.
6. Bailey LB, Berry RJ. 2005. Folic acid supplementation and the occurrence of congenital heart defects, orofacial clefts, multiple births, and miscarriage. Am J Clin Nutr 81: 1213S-1217S.
7. Baker L, Piddington R, Goldman A, Egler J, Moehring J. 1990. Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia 33: 593-596.
8. Beck SL. 1999. Contributions of dam and conceptus to differences in sensitivity to valproic acid among C57 black and SWV mice. Reprod Toxicol 13: 353-360.
9. Beemster P, Groenen P, Steegers-Theunissen R. 2002. Involvement of inositol in reproduction. Nutr Rev 60: 80-87.
10. Blanton SH, Henry RR, Yuan Q, Mulliken JB, Stal S, Finnell RH, Hecht JT. 2011. Folate pathway and nonsyndromic cleft lip and palate. Birth Defects Res A Clin Mol Teratol 91: 50-60.
11. Blencowe H, Cousens S, Modell B, Lawn J. 2010. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol 3: i110-i121.
12. Blom HJ, Shaw GM, den Heijer M, Finnell RH. 2006. Neural tube defects and folate: Case far from closed. Nat Rev Neurosci 7: 724-731.
13. Botto LD, Yang Q. 2000. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 151: 862-877.
14. Botto LD, Mulinare J, Erickson JD. 2003b. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet Part A 121A: 95-101.
15. Boyles AL, DeRoo LA, Lie RT, Taylor JA, Jugessur A, Murray JC, Wilcox AJ. 2010. Maternal alcohol consumption, alcohol metabolism genes, and the risk of oral clefts: A population-based case-control study in Norway, 1996-2001. Am J Epidemiol 172: 924-931.
16. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. 2001. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 70: 391-394.
17. Brauer PR, Tierney BJ. 2004. Consequences of elevated homocysteine during embryonic development and possible modes of action. Curr Pharm Des 10: 2719-2732.
18. Breen DP, Davenport RJ. 2006. Teratogenicity of antiepileptic drugs. Br Med J 333: 615-616.
19. Brender JD, Suarez L. 1990. Paternal occupation and anencephaly. Am J Epidemiol 131: 517-521.
20. Brender J, Suarez L, Hendricks K, Baetz RA, Larsen R. 2002. Parental occupation and neural tube defect-affected pregnancies among Mexican Americans. J Occup Environ Med 44: 650-656.
21. Buehler BA, Delimont D, van Waes M, Finnell RH. 1990. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 322: 1567-1572.
22. Burren KA, Savery D, Massa V, Kok RM, Scott JM, Blom HJ, Copp AJ, Greene ND. 2008. Gene-environment interactions in the causation of neural tube defects: Folate deficiency increases susceptibility conferred by loss of Pax3 function. Hum Mol Genet 17: 3675-3685.
23. Campbell LR, Dayton DH, Sohal GS. 1986. Neural tube defects: A review of human and animal studies on the etiology of neural tube defects. Teratology 34: 171-187.
24. Carmichael SL, Shaw GM, Selvin S, Schaffer DM. 2003. Diet quality and risk of neural tube defects. Med Hypotheses 60: 351-355.
25. Chabra S, Gleason CA, Seidel K, Williams MA. 2011. Rising prevalence of gastroschisis in Washington State. J Toxicol Environ Health A 74: 336-345.
26. Collins JS, Atkinson KK, Dean JH, Best RG, Stevenson RE. 2011. Long term maintenance of neural tube defects prevention in a high prevalence state. J Pediatr (Epub).
27. Correa M, Manrique HM, Font L, Escrig MA, Aragon CM. 2008. Reduction in the anxiolytic effects of ethanol by centrally formed acetaldehyde: The role of catalase inhibitors and acetaldehyde-sequestering agents. Psychopharmacology (Berl) 200: 455-464.
28. Czeizel AE. 2000. Primary prevention of neural-tube defects and some other major congenital abnormalities: Recommendations for the appropriate use of folic acid during pregnancy. Paediatr Drugs 2: 437-449.
29. Dansky LV, Finnell RH. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 5: 301-335.
30. Davidson CM, Northrup H, King TM, Fletcher JM, Townsend I, Tyerman GH, Au KS. 2008. Genes in glucose metabolism and association with spina bifida. Reprod Sci 15: 51-58.
31. Dawson JE, Raymond AM, Winn LM. 2006. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol 211: 124-132.
32. Dean JC, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. 2002. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 39: 251-259.
33. Dean JC, Robertson Z, Reid V, Wang Q, Hailey H, Moore S, Rasalam AD, Turnpenny P, Lloyd D, Shaw D, Little J. 2008. A high frequency of the MTHFR 677C>T polymorphism in Scottish women with epilepsy: Possible role in pathogenesis. Seizure 17: 269-275.
34. Deen JL, Vos T, Huttly SR, Tulloch J. 1999. Injuries and noncommunicable diseases: Emerging health problems of children in developing countries. Bull World Health Organ 77: 518-524.
35. Delgado-Escueta AV, Janz D. 1992. Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 42: 149-160.
36. Dheen ST, Tay SS, Boran J, Ting LW, Kumar SD, Fu J, Ling EA. 2009. Recent studies on neural tube defects in embryos of diabetic pregnancy: An overview. Curr Med Chem 16: 2345-2354.
37. Eriksson UJ, Borg LA. 1991. Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformations in vitro. Diabetologia 34: 325-331.
38. Eriksson UJ, Siman CM. 1996. Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring. Diabetes 45: 1497-1502.
39. Eriksson UJ, Borg LA, Cederberg J, Nordstrand H, Siman CM, Wentzel C, Wentzel P. 2000. Pathogenesis of diabetes-induced congenital malformations. Ups J Med Sci 105: 53-84.
40. Eriksson UJ, Cederberg J, Wentzel P. 2003. Congenital malformations in offspring of diabetic mothers-Animal and human studies. Rev Endocr Metab Disord 4: 79-93.
41. Faiella A, Wernig M, Consalez GG, Hostick U, Hofmann C, Hustert E, Boncinelli E, Balling R, Nadeau JH. 2000. A mouse model for valproate teratogenicity: Parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 9: 227-236.
42. Feldkamp ML, Alder SC, Carey JC. 2008. A case control population-based study investigating smoking as a risk factor for gastroschisis in Utah, 1997-2005. Birth Defects Res A Clin Mol Teratol 82: 768-775.
43. Fine EL, Horal M, Chang TI, Fortin G, Loeken MR. 1999. Evidence that elevated glucose causes altered gene expression, apoptosis, and neural tube defects in a mouse model of diabetic pregnancy. Diabetes 48: 2454-2462.
44. Finnell RH. 1991. Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects. Pharmacol Toxicol 69: 223-227.
45. Finnell RH, Shaw GM, Lammer EJ, Brandl KL, Carmichael SL, Rosenquist TH. 2004. Gene-nutrient interactions: Importance of folates and retinoids during early embryogenesis. Toxicol Appl Pharmacol 198: 75-85.
46. Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E, Granstrom ML. 2004. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62: 28-32.
47. German J, Ehlers KH, Kowal A, De George FV, Engle MA, Passarge E. 1970. Possible teratogenicity of trimethadione and paramethadione. Lancet 2: 261-262.
48. Goldman AS, Baker L, Piddington R, Marx B, Herold R, Egler J. 1985. Hyperglycemia-induced teratogenesis is mediated by a functional deficiency of arachidonic acid. Proc Natl Acad Sci USA 82: 8227-8231.
49. Graham JM Jr, Shaw GM. 2005. Gene-environment interactions in rare diseases that include common birth defects. Birth Defects Res A Clin Mol Teratol 73: 865-867.
50. Grewal J, Carmichael SL, Ma C, Lammer EJ, Shaw GM. 2008. Maternal periconceptional smoking and alcohol consumption and risk for select congenital anomalies. Birth Defects Res A Clin Mol Teratol 82: 519-526.
51. Groenen PM, Peer PG, Wevers RA, Swinkels DW, Franke B, Mariman EC, Steegers-Theunissen RP. 2003. Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. Am J Obstet Gynecol 189: 1713-1719.
52. Hagay ZJ, Weiss Y, Zusman I, Peled-Kamar M, Reece EA, Eriksson UJ, Groner Y. 1995. Prevention of diabetes-associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. Am J Obstet Gynecol 173: 1036-1041.
53. Hall JL, Harris MJ, Juriloff DM. 1997. Effect of multifactorial genetic liability to exencephaly on the teratogenic effect of valproic acid in mice. Teratology 55: 306-313.
54. Harris MJ, Juriloff DM. 2010. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res A Clin Mol Teratol 88: 653-669.
55. Heilig CW, Saunders T, Brosius FC III, Moley K, Heilig K, Baggs R, Guo L, Conner D. 2003. Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc Natl Acad Sci USA 100: 15613-15618.
56. Hendricks KA, Nuno OM, Suarez L, Larsen R. 2001. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 12: 630-635.
57. Hobbs CA, James SJ, Jernigan S, Melnyk S, Lu Y, Malik S, Cleves MA. 2006. Congenital heart defects, maternal homocysteine, smoking, and the 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene: Evaluating gene-environment interactions. Am J Obstet Gynecol 194: 218-224.
58. Hobbs CA, Cleves MA, Karim MA, Zhao W, MacLeod SL. 2010. Maternal folate-related gene environment interactions and congenital heart defects. Obstet Gynecol 116: 316-322.
59. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM. 2001. The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132-1138.
60. Honein MA, Moore CA, Watkins ML. 2003. Subfertility and prepregnancy overweight/obesity: Possible interaction between these risk factors in the etiology of congenital renal anomalies. Birth Defects Res A Clin Mol Teratol 67: 572-577.
61. Hvas CL, Henriksen TB, Østergaard JR. 2000. Birth weight in offspring of women with epilepsy. Epidemiol Rev 22: 275-282.
62. Hwang SJ, Beaty TH, Panny SR, Street NA, Joseph JM, Gordon S, McIntosh I, Francomano CA. 1995. Association study of transforming growth factor alpha (TGF alpha) TaqI polymorphism and oral clefts: Indication of gene-environment interaction in a population-based sample of infants with birth defects. Am J Epidemiol 141: 629-636.
63. Ingelman-Sundberg M, Sim SC. 2010. Intronic polymorphisms of cytochromes P450. Hum Genomics 4: 402-405.
64. Jakubowski H, Perla-Kajan J, Finnell RH, Cabrera RM, Wang H, Gupta S, Kruger WD, Kraus JP, Shih DM. 2009. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J 23: 1721-1727.
65. Janssen PA, Rothman I, Schwartz SM. 1996. Congenital malformations in newborns of women with established and gestational diabetes in Washington State, 1984-91. Paediatr Perinat Epidemiol 10: 52-63.
66. Jauniaux E, Burton GJ. 2007. Morphological and biological effects of maternal exposure to tobacco smoke on the feto-placental unit. Early Hum Dev 83: 699-706.
67. Johansson I, Ingelman-Sundberg M. 2010. Genetic polymorphism and toxicology-With emphasis on cytochrome P450. Toxicol Sci 120: 1-13.
68. Jones KL, Smith DW, Ulleland CN, Streissguth P. 1973. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 1: 1267-1271.
69. Jones KL, Lacro RV, Johnson KA, Adams J. 1989. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320: 1661-1666.
70. Joost HG, Thorens B. 2001. The extended GLUT-family of sugar/polyol transport facilitators: Nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 18: 247-256.
71. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, Thorens B. 2002. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282: E974-E976.
72. Kallen K. 1998. Maternal smoking, body mass index, and neural tube defects. Am J Epidemiol 147: 1103-1111.
73. Kambe F, Nomura Y, Okamoto T, Seo H. 1996. Redox regulation of thyroid-transcription factors, Pax-8 and TTF-1, is involved in their increased DNA-binding activities by thyrotropin in rat thyroid FRTL-5cells. Mol Endocrinol 10: 801-812.
74. Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. 1999. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33: 145-158.
75. Khandelwal M, Reece EA, Wu YK, Borenstein M. 1998. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology 57: 79-84.
76. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. 2001. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11: 803-808.
77. King GL, Loeken MR. 2004. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122: 333-338.
78. Kini U, Lee R, Jones A, Smith S, Ramsden S, Fryer A, Clayton-Smith J. 2007. Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet 50: 411-420.
79. Kuciene R, Dulskiene V. 2010. Parental cigarette smoking and the risk of congenital heart septal defects. Medicina (Kaunas) 46: 635-641.
80. Kumar V, Bustin SA, McKay IA. 1995. Transforming growth factor alpha. Cell Biol Int 19: 373-388.
81. Lammer EJ, Iovannisci DM, Tom L, Schultz K, Shaw GM. 2008. Gastroschisis: A gene-environment model involving the VEGF-NOS3 pathway. Am J Med Genet Part C 148C: 213-218.
82. Lemoine P, Harousseau H, Borteyru JP, Menuet JC. 1968. Les enfants des parents alcoholiques: Anomalies observees a propos de 127 cas (The children of alcoholic parents: Anomalies observed in 127 cases). Quest Medical 25: 476-482.
83. Li R, Thorens B, Loeken MR. 2007. Expression of the gene encoding the high-Km glucose transporter 2 by the early postimplantation mouse embryo is essential for neural tube defects associated with diabetic embryopathy. Diabetologia 50: 682-689.
84. Li ZW, Liu JM, Ren AG, Zhang L, Guo ZY, Li Z. 2008. Maternal passive smoking and the risk of neural tube defects: A case-control study in Shanxi province, China. Zhonghua Liu Xing Bing Xue Za Zhi 29: 417-420.
85. Lie RT, Wilcox AJ, Taylor J, Gjessing HK, Saugstad OD, Aabyholm F, Vindenes H. 2008. Maternal smoking and oral clefts: The role of detoxification pathway genes. Epidemiology 19: 606-615.
86. Little J, Cardy A, Arslan MT, Gilmour M, Mossey PA. 2004. Smoking and orofacial clefts: A United Kingdom-based case-control study. Cleft Palate Craniofac J 41: 381-386.
87. Loeken MR. 2005. Current perspectives on the causes of neural tube defects resulting from diabetic pregnancy. Am J Med Genet Part C 135C: 77-87.
88. Loeken MR. 2006. Advances in understanding the molecular causes of diabetes-induced birth defects. J Soc Gynecol Investig 13: 2-10.
89. Lorente C, Cordier S, Goujard J, Ayme S, Bianchi F, Calzolari E, De Walle HE, Knill-Jones R. 2000. Tobacco and alcohol use during pregnancy and risk of oral clefts. Occupational Exposure and Congenital Malformation Working Group. Am J Public Health 90: 415-419.
90. Lu W, Zhu H, Wen S, Laurent C, Shaw GM, Lammer EJ, Finnell RH. 2007. Screening for novel PAX3 polymorphisms and risks of spina bifida. Birth Defects Res A Clin Mol Teratol 79: 45-49.
91. Lundberg YW, Wing MJ, Xiong W, Zhao J, Finnell RH. 2003. Genetic dissection of hyperthermia-induced neural tube defects in mice. Birth Defects Res A Clin Mol Teratol 67: 409-413.
92. Maeda Y, Akazawa S, Akazawa M, Takao Y, Trocino RA, Takino H, Kawasaki E, Yokota A, Okuno S, Nagataki S. 1993. Glucose transporter gene expression in rat conceptus during early organogenesis and exposure to insulin-induced hypoglycemic serum. Acta Diabetol 30: 73-78.
93. Malik S, Cleves MA, Honein MA, Romitti PA, Botto LD, Yang S, Hobbs CA. 2008. Maternal smoking and congenital heart defects. Pediatrics 121: e810-e816.
94. Malm H, Kajantie E, Kivirikko S, Kaariainen H, Peippo M, Somer M. 2002. Valproate embryopathy in three sets of siblings: Further proof of hereditary susceptibility. Neurology 59: 630-633.
95. Matsumoto K, Akazawa S, Ishibashi M, Trocino RA, Matsuo H, Yamasaki H, Yamaguchi Y, Nagamatsu S, Nagataki S. 1995. Abundant expression of GLUT1 and GLUT3 in rat embryo during the early organogenesis period. Biochem Biophys Res Commun 209: 95-102.
96. Meador KJ, Pennell PB, Harden CL, Gordon JC, Tomson T, Kaplan PW, Holmes GL, French JA, Hauser WA, Wells PG, Cramer JA. HOPE Work Group. 2008. Pregnancy registries in epilepsy: A consensus statement on health outcomes. Neurology 71: 1109-1117.
97. Meeker JD, Missmer SA, Cramer DW, Hauser R. 2007. Maternal exposure to second-hand tobacco smoke and pregnancy outcome among couples undergoing assisted reproduction. Hum Reprod 22: 337-345.
98. Mills JL, Baker L, Goldman AS. 1979. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes 28: 292-293.
99. Mitanchez D. 2010. Foetal and neonatal complications in gestational diabetes: Perinatal mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal complications. Diabetes Metab 36: 617-627.
100. Morgan SC, Relaix F, Sandell LL, Loeken MR. 2008. Oxidative stress during diabetic pregnancy disrupts cardiac neural crest migration and causes outflow tract defects. Birth Defects Res A Clin Mol Teratol 82: 453-463.
101. Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT. 2003. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 18: 769-771.
102. Murray JC. 2002. Gene/environment causes of cleft lip and/or palate. Clin Genet 61: 248-256.
103. Myrianthopoulos NC, Melnick M. 1987. Studies in neural tube defects. I: Epidemiologic and etiologic aspects. Am J Med Genet 26: 783-796.
104. Naruse I, Collins MD, Scott WJ Jr. 1988. Strain differences in the teratogenicity induced by sodium valproate in cultured mouse embryos. Teratology 38: 87-96.
105. Obican SG, Finnell RH, Mills JL, Shaw GM, Scialli AR. 2010. Folic acid in early pregnancy: A public health success story. FASEB J 24: 4167-4174.
106. Ohtsuki S, Kikkawa T, Hori S, Terasaki T. 2006. Modulation and compensation of the mRNA expression of energy related transporters in the brain of glucose transporter 1-deficient mice. Biol Pharm Bull 29: 1587-1591.
107. Ottman R. 1990. An epidemiologic approach to gene-environment interaction. Genet Epidemiol 7: 177-185.
108. Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, Rozen R, Oakley GP Jr, Adams MJ Jr. 1996. 5, 10-Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 63: 610-614.
109. Ozerol E, Ozerol I, Gokdeniz R, Temel I, Akyol O. 2004. Effect of smoking on serum concentrations of total homocysteine, folate, vitamin B12, and nitric oxide in pregnancy: A preliminary study. Fetal Diagn Ther 19: 145-148.
110. Padmanabhan R, Shafiullah MM. 2003. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 43: 29-40.
111. Pani L, Horal M, Loeken MR. 2002a. Polymorphic susceptibility to the molecular causes of neural tube defects during diabetic embryopathy. Diabetes 51: 2871-2874.
112. Pani L, Horal M, Loeken MR. 2002b. Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: Implications for Pax-3-dependent development and tumorigenesis. Genes Dev 16: 676-680.
113. Parle-McDermott A, Pangilinan F, Mills JL, Kirke PN, Gibney ER, Troendle J, O'Leary VB, Molloy AM, Conley M, Scott JM, Brody LC. 2007. The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet Part A 143A: 1174-1180.
114. Pavlinkova G, Salbaum JM, Kappen C. 2009. Maternal diabetes alters transcriptional programs in the developing embryo. BMC Genomics 10: 274.
115. Pennell PB. 2006. 2005 AES annual course: Evidence used to treat women with epilepsy. Epilepsia 47: 46-453.
116. Perucca E. 2005. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 4: 781-786.
117. Phelan SA, Ito M, Loeken MR. 1997. Neural tube defects in embryos of diabetic mice: Role of the Pax-3 gene and apoptosis. Diabetes 46: 1189-1197.
118. Prescott NJ, Winter RM, Malcolm S. 2001. Nonsyndromic cleft lip and palate: Complex genetics and environmental effects. Ann Hum Genet 65: 505-515.
119. Quadros EV, Regec AL, Khan KM, Quadros E, Rothenberg SP. 1999. Transcobalamin II synthesized in the intestinal villi facilitates transfer of cobalamin to the portal blood. Am J Physiol 277: G161-G166.
120. Ray JG, Thompson MD, Vermeulen MJ, Meier C, Wyatt PR, Wong PY, Summers AM, Farrell SA, Cole DE. 2007. Metabolic syndrome features and risk of neural tube defects. BMC Pregnancy Childbirth 7: 21.
121. Reece EA, Homko CJ. 1993. Diabetes-related complications of pregnancy. J Natl Med Assoc 85: 537-545.
122. Reece EA, Gabrielli S, Abdalla M. 1988. The prevention of diabetes-associated birth defects. Semin Perinatol 12: 292-301.
123. Reece EA, Wiznitzer A, Homko CJ, Hagay Z, Wu YK. 1996a. Synchronization of the factors critical for diabetic teratogenesis: An in vitro model. Am J Obstet Gynecol 174: 1284-1288.
124. Reece EA, Wu YK, Wiznitzer A, Homko C, Yao J, Borenstein M, Sloskey G. 1996b. Dietary polyunsaturated fatty acid prevents malformations in offspring of diabetic rats. Am J Obstet Gynecol 175: 818-823.
125. Roy M, Leclerc D, Wu Q, Gupta S, Kruger WD, Rozen R. 2008. Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency. J Cell Biochem 105: 467-476.
126. Salbaum JM, Kappen C. 2010. Neural tube defect genes and maternal diabetes during pregnancy. Birth Defects Res A Clin Mol Teratol 88: 601-611.
127. Savona-Ventura C, Gatt M. 2004. Embryonal risks in gestational diabetes mellitus. Early Hum Dev 79: 59-63.
128. Sever LE. 1995. Looking for causes of neural tube defects: Where does the environment fit in? Environ Health Perspect 103: 165-171.
129. Shaw GM, Jensvold NG, Wasserman CR, Lammer EJ. 1994. Epidemiologic characteristics of phenotypically distinct neural tube defects among 0.7 million California births, 1983-1987. Teratology 49: 143-149.
130. Shaw GM, Velie EM, Schaffer D. 1996. Risk of neural tube defect-affected pregnancies among obese women. JAMA 275: 1093-1096.
131. Shaw GM, Todoroff K, Velie EM, Lammer EJ. 1998a. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 57: 1-7.
132. Shaw GM, Wasserman CR, Murray JC, Lammer EJ. 1998b. Infant TGF-alpha genotype, orofacial clefts, and maternal periconceptional multivitamin use. Cleft Palate Craniofac J 35: 366-370.
133. Shaw GM, Todoroff K, Schaffer DM, Selvin S. 1999a. Periconceptional nutrient intake and risk for neural tube defect-affected pregnancies. Epidemiology 10: 711-7116.
134. Shaw GM, Wasserman CR, O'Malley CD, Nelson V, Jackson RJ. 1999b. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology 10: 60-66.
135. Shaw GM, Todoroff K, Schaffer DM, Selvin S. 2000. Maternal height and prepregnancy body mass index as risk factors for selected congenital anomalies. Paediatr Perinat Epidemiol 14: 234-239.
136. Shaw GM, Quach T, Nelson V, Carmichael SL, Schaffer DM, Selvin S, Yang W. 2003. Neural tube defects associated with maternal periconceptional dietary intake of simple sugars and glycemic index. Am J Clin Nutr 78: 972-978.
137. Shaw GM, Carmichael SL, Vollset SE, Yang W, Finnell RH, Blom H, Midttun O, Ueland PM. 2009. Mid-pregnancy cotinine and risks of orofacial clefts and neural tube defects. J Pediatr 154: 17-19.
138. Shea AK, Steiner M. 2008. Cigarette smoking during pregnancy. Nicotine Tob Res 10: 267-278.
139. Shepard TH, Tanimura T, Robkin MA. 1970. Energy metabolism in early mammalian embryos. Symp Soc Dev Biol 29: 42-58.
140. Shi M, Christensen K, Weinberg CR, Romitti P, Bathum L, Lozada A, Morris RW, Lovett M, Murray JC. 2007. Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants. Am J Hum Genet 80: 76-90.
141. Shi M, Wehby GL, Murray JC. 2008. Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects. Birth Defects Res C Embryo Today 84: 16-29.
142. Sivan E, Reece EA, Wu YK, Homko CJ, Polansky M, Borenstein M. 1996. Dietary vitamin E prophylaxis and diabetic embryopathy: Morphologic and biochemical analysis. Am J Obstet Gynecol 175: 793-799.
143. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1: 339-340.
144. Spiegelstein O, Chatterjie N, Alexander G, Finnell RH. 2003. Teratogenicity of valproate conjugates with anticonvulsant activity in mice. Epilepsy Res 57: 145-152.
145. Spiegelstein O, Gould A, Wlodarczyk B, Tsie M, Lu X, Le C, Troen A, Selhub J, Piedrahita JA, Salbaum JM, Kappen C, Melnyk S, James J, Finnell RH. 2005. Developmental consequences of in utero sodium arsenate exposure in mice with folate transport deficiencies. Toxicol Appl Pharmacol 203: 18-26.
146. Styrud J, Eriksson UJ. 1992. Development of rat embryos in culture media containing different concentrations of normal and diabetic rat serum. Teratology 46: 473-483.
147. Suarez L, Felkner M, Brender JD, Canfield M, Hendricks K. 2008. Maternal exposures to cigarette smoke, alcohol, and street drugs and neural tube defect occurrence in offspring. Matern Child Health J 12: 394-401.
148. Suarez L, Ramadhani T, Felkner M, Canfield MA, Brender JD, Romitti PA, Sun L. 2011. Maternal smoking, passive tobacco smoke, and neural tube defects. Birth Defects Res A Clin Mol Teratol 91: 29-33.
149. Suzuki N, Svensson K, Eriksson UJ. 1996. High glucose concentration inhibits migration of rat cranial neural crest cells in vitro. Diabetologia 39: 401-411.
150. Takao Y, Akazawa S, Matsumoto K, Takino H, Akazawa M, Trocino RA, Maeda Y, Okuno S, Kawasaki E, Uotani S, et al. 1993. Glucose transporter gene expression in rat conceptus during high glucose culture. Diabetologia 36: 696-706.
151. Tanimura T, Shepard TH. 1970. Glucose metabolism by rat embryos in vitro. Proc Soc Exp Biol Med 135: 51-54.
152. Torfs CP, Christianson RE, Iovannisci DM, Shaw GM, Lammer EJ. 2006. Selected gene polymorphisms and their interaction with maternal smoking, as risk factors for gastroschisis. Birth Defects Res A Clin Mol Teratol 76: 723-730.
153. Trocino RA, Akazawa S, Takino H, Takao Y, Matsumoto K, Maeda Y, Okuno S, Nagataki S. 1994. Cellular-tissue localization and regulation of the GLUT-1 protein in both the embryo and the visceral yolk sac from normal and experimental diabetic rats during the early postimplantation period. Endocrinology 134: 869-878.
154. van der Linden IJ, den Heijer M, Afman LA, Gellekink H, Vermeulen SH, Kluijtmans LA, Blom HJ. 2006. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med 84: 1047-1054.
155. van der Linden IJ, Nguyen U, Heil SG, Franke B, Vloet S, Gellekink H, den Heijer M, Blom HJ. 2007. Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida. Mol Genet Metab 91: 98-103.
156. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. 1995. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346: 1070-1071.
157. van Rooij IA, Wegerif MJ, Roelofs HM, Peters WH, Kuijpers-Jagtman AM, Zielhuis GA, Merkus HM, Steegers-Theunissen RP. 2001. Smoking, genetic polymorphisms in biotransformation enzymes, and nonsyndromic oral clefting: A gene-environment interaction. Epidemiology 12: 502-507.
158. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. 2009. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50: 2130-2139.
159. Venners SA, Wang X, Chen C, Wang L, Chen D, Guang W, Huang A, Ryan L, O'Connor J, Lasley B, Overstreet J, Wilcox A, Xu X. 2004. Paternal smoking and pregnancy loss: A prospective study using a biomarker of pregnancy. Am J Epidemiol 159: 993-1001.
160. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA. 2005. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64: 949-954.
161. Volcik KA, Shaw GM, Lammer EJ, Zhu H, Finnell RH. 2003a. Evaluation of infant methylenetetrahydrofolate reductase genotype, maternal vitamin use, and risk of high versus low level spina bifida defects. Birth Defects Res A Clin Mol Teratol 67: 154-157.
162. Volcik KA, Shaw GM, Zhu H, Lammer EJ, Laurent C, Finnell RH. 2003b. Associations between polymorphisms within the thymidylate synthase gene and spina bifida. Birth Defects Res A Clin Mol Teratol 67: 924-928.
163. Vurucu S, Demirkaya E, Kul M, Unay B, Gul D, Akin R, Gokcay E. 2008. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy. Prog Neuropsychopharmacol Biol Psychiatry 32: 844-848.
164. Waller DK, Mills JL, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Rhoads GG. 1994. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol 170: 541-548.
165. Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz AM, Gallaway MS, Correa A. 2007. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161: 745-750.
166. Watkins ML, Botto LD. 2001. Maternal prepregnancy weight and congenital heart defects in offspring. Epidemiology 12: 439-446.
167. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. 1996. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 7: 507-512.
168. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. 2003. Maternal obesity and risk for birth defects. Pediatrics 111: 1152-1158.
169. Wentzel P, Thunberg L, Eriksson UJ. 1997. Teratogenic effect of diabetic serum is prevented by supplementation of superoxide dismutase and N-acetylcysteine in rat embryo culture. Diabetologia 40: 7-14.
170. Wentzel P, Wentzel CR, Gareskog MB, Eriksson UJ. 2001. Induction of embryonic dysmorphogenesis by high glucose concentration, disturbed inositol metabolism, and inhibited protein kinase C activity. Teratology 63: 193-201.
171. Werler MM, Louik C, Shapiro S, Mitchell AA. 1996. Prepregnant weight in relation to risk of neural tube defects. JAMA 275: 1089-1092.
172. White FM, Cohen FG, Sherman G, McCurdy R. 1988. Chemicals, birth defects and stillbirths in New Brunswick: Associations with agricultural activity. CMAJ 138: 117-124.
173. Wilson JG, Warkany J. 1965. Teratology: Principles and techniques. Chicago: University of Chicago Press. 279 p.
174. Wiltse J. 2005. Mode of action: Inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-Developmental effects of valproic acid. Crit Rev Toxicol 35: 727-738.
175. Wlodarczyk B, Spiegelstein O, Gelineau-van Waes J, Vorce RL, Lu X, Le CX, Finnell RH. 2001. Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice. Toxicol Appl Pharmacol 177: 238-246.
176. Wlodarczyk BJ, Cabrera RM, Hill DS, Bozinov D, Zhu H, Finnell RH. 2006a. Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. Neurotoxicology 27: 547-557.
177. Wlodarczyk BJ, Tang LS, Triplett A, Aleman F, Finnell RH. 2006b. Spontaneous neural tube defects in splotch mice supplemented with selected micronutrients. Toxicol Appl Pharmacol 213: 55-63.
178. Wu X, Bishopric NH, Discher DJ, Murphy BJ, Webster KA. 1996. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 16: 1035-1046.
179. Zabihi S, Loeken MR. 2010. Understanding diabetic teratogenesis: Where are we now and where are we going? Birth Defects Res A Clin Mol Teratol 88: 779-790.
180. Zeiger JS, Beaty TH, Liang KY. 2005. Oral clefts, maternal smoking, and TGFA: A meta-analysis of gene-environment interaction. Cleft Palate Craniofac J 42: 58-63.
181. Zhao Z, Reece EA. 2005. Experimental mechanisms of diabetic embryopathy and strategies for developing therapeutic interventions. J Soc Gynecol Investig 12: 549-557.
182. Zhu H, Junker WM, Finnell RH, Brown S, Shaw GM, Lammer EJ, Canfield M, Hendricks K. 2003. Lack of association between ZIC2 and ZIC3 genes and the risk of neural tube defects (NTDs) in Hispanic populations. Am J Med Genet Part A 116A: 414-415.
183. Zhu H, Curry S, Wen S, Wicker NJ, Shaw GM, Lammer EJ, Yang W, Jafarov T, Finnell RH. 2005. Are the betaine-homocysteine methyltransferase (BHMT and BHMT2) genes risk factors for spina bifida and orofacial clefts? Am J Med Genet Part A 135A: 274-277.
184. Zhu H, Yang W, Lu W, Zhang J, Shaw GM, Lammer EJ, Finnell RH. 2006. A known functional polymorphism (Ile120Val) of the human PCMT1 gene and risk of spina bifida. Mol Genet Metab 87: 66-70.
185. Zhu H, Enaw JO, Ma C, Shaw GM, Lammer EJ, Finnell RH. 2007. Association between CFL1 gene polymorphisms and spina bifida risk in a California population. BMC Med Genet 8: 12.